Simocyclinone D8 turns on against Gram-negative bacteria in a clinical setting

Bioorg Med Chem Lett. 2010 Feb 1;20(3):1202-4. doi: 10.1016/j.bmcl.2009.11.135. Epub 2009 Dec 4.

Abstract

Simocyclinone D8 (SD8) is known to affect Gram-positive bacteria only. By testing SD8 against several clinical isolates, we showed that SD8 resulted very active against Gram-negative bacteria from clinical specimens, while it was shown inactive against laboratory strains. The activity against the former was in part due to enhanced drug entry. In addition, SD8 appears to share chromosome- and plasmid-mediated resistance mechanisms with fluoroquinolones.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / chemistry*
  • Anti-Bacterial Agents / metabolism*
  • Anti-Bacterial Agents / pharmacology
  • Coumarins / chemistry
  • Coumarins / metabolism
  • Coumarins / pharmacology
  • Escherichia coli / drug effects*
  • Escherichia coli / growth & development*
  • Escherichia coli / isolation & purification
  • Escherichia coli K12 / drug effects
  • Escherichia coli K12 / growth & development
  • Fluoroquinolones / pharmacology
  • Glycosides / chemistry
  • Glycosides / metabolism
  • Glycosides / pharmacology
  • Humans
  • Klebsiella pneumoniae / drug effects*
  • Klebsiella pneumoniae / growth & development*
  • Klebsiella pneumoniae / isolation & purification
  • Microbial Sensitivity Tests
  • Staphylococcus aureus / drug effects
  • Staphylococcus aureus / growth & development

Substances

  • Anti-Bacterial Agents
  • Coumarins
  • Fluoroquinolones
  • Glycosides
  • simocyclinone D8